Exicure Inc (XCUR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
October 2018
43
About the Report
About the Report
Summary
Exicure Inc (Exicure), formerly AuraSense Therapeutics LLC is a biotechnology company that discovers, develops, and commercializes immunomodulatory and gene silencing drugs based on 3-dimensional spherical nucleic acid constructs. The company's technology portfolio includes SNA gene regulation platform and genetic analysis tools. Its pipeline spans SNA based therapeutics for the treatment of psoriasis, fibrosis, diabetic ulcers, bladder cancer, and inflammation. Exicure SNA's are also used as immunotherapeutic agents for the treatment of cancer and other infectious diseases. The company works in collaboration with various pharmaceutical and biotechnology companies for exploring its SNA platform application against multiple diseases. Exicure is headquartered in Skokie, Illinois, the US.
Exicure Inc (XCUR)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Exicure Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Exicure Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Exicure Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Exicure Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Exicure Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Exicure Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Exicure Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Exicure Secures Venture Funding 12
Exicure Raises USD14.8 Million Financing 13
AuraSense Therapeutics Raises USD4.4 Million in Extended Series C Financing 14
AuraSense Therapeutics Raises USD13.6 Million in Series C Financing 15
AuraSense Therapeutics Raises Funds Through Extended Series B Financing 16
Private Equity 17
Exicure to Raise USD22 Million in Private Placement of Shares 17
Partnerships 19
Exicure Enters into Agreement with Ohio State University 19
Merger 20
Exicure and Max-1 Acquisition Merges in Reverse Merger Transaction 20
Licensing Agreements 21
Purdue Pharma Enters into Licensing Agreement with Exicure 21
Exicure Enters into Licensing Agreement with Northwestern University 22
Exicure Enters into Licensing Agreement with Northwestern University for SNA Technology 23
Equity Offering 24
Exicure Plans to Raise up to USD119.1 Million in Private Placement of Shares 24
Exicure Raises Additional USD11.2 Million in Private Placement of Shares 25
Exicure Raises USD20 Million in Private Placement 26
Exicure Inc-Key Competitors 27
Exicure Inc-Key Employees 28
Exicure Inc-Locations And Subsidiaries 29
Head Office 29
Recent Developments 30
Financial Announcements 30
Aug 06, 2018: Exicure provides update on corporate progress and second quarter 2018 financial results 30
May 15, 2018: Exicure Announces First Quarter 2018 Financial Results 32
Mar 09, 2018: Exicure Reports Full Year 2017 Financial Results And Corporate Progress 34
Nov 14, 2017: Exicure Reports Third Quarter 2017 Financial Results and Provides Business Update 36
Corporate Communications 38
Apr 20, 2018: Exicure Appoints Matthias Schroff As Chief Operating Officer 38
Clinical Trials 39
Oct 02, 2018: Exicure presents first data demonstrating both oral Delivery and liver Delivery of Spherical Nucleic Acid constructs in animal models 39
Jun 14, 2018: Exicure to Present Data at the Cure Spinal Muscular Atrophy Annual Conference in Dallas 40
Other Significant Developments 41
May 23, 2018: Exicure To Begin Trading on United States OTCQB Under the Symbol XCUR 41
May 27, 2017: Investors flock to exicure s IPO-Luye Pharma s strategy of investment in novel biopharmaceuticals receives optimistic outlook 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43
List of Figure
List of Figures
Exicure Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Exicure Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Exicure Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Exicure Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Exicure Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Exicure Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Exicure Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Exicure Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List of Table
List of Tables
Exicure Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Exicure Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Exicure Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Exicure Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Exicure Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Exicure Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Exicure Secures Venture Funding 12
Exicure Raises USD14.8 Million Financing 13
AuraSense Therapeutics Raises USD4.4 Million in Extended Series C Financing 14
AuraSense Therapeutics Raises USD13.6 Million in Series C Financing 15
AuraSense Therapeutics Raises Funds Through Extended Series B Financing 16
Exicure to Raise USD22 Million in Private Placement of Shares 17
Exicure Enters into Agreement with Ohio State University 19
Exicure and Max-1 Acquisition Merges in Reverse Merger Transaction 20
Purdue Pharma Enters into Licensing Agreement with Exicure 21
Exicure Enters into Licensing Agreement with Northwestern University 22
Exicure Enters into Licensing Agreement with Northwestern University for SNA Technology 23
Exicure Plans to Raise up to USD119.1 Million in Private Placement of Shares 24
Exicure Raises Additional USD11.2 Million in Private Placement of Shares 25
Exicure Raises USD20 Million in Private Placement 26
Exicure Inc, Key Competitors 27
Exicure Inc, Key Employees 28
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.